Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://lib.inmeds.com.ua:8080/jspui/handle/lib/4450
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorMorganti, S.-
dc.contributor.authorIvanova, M.-
dc.contributor.authorFerraro, E.-
dc.contributor.authorAscione, L.-
dc.contributor.authorVivanet, G.-
dc.contributor.authorBonizzi, G.-
dc.contributor.authorCurigliano, G.-
dc.contributor.authorFusco, N.-
dc.contributor.authorCriscitiello, C.-
dc.date.accessioned2023-01-11T13:24:21Z-
dc.date.available2023-01-11T13:24:21Z-
dc.date.issued2022-
dc.identifier.issn2578-532X-
dc.identifier.urihttp://lib.inmeds.com.ua:8080/jspui/handle/lib/4450-
dc.description.abstractLoss of HER2 in previously HER2-positive breast tumors is not rare, occurring in up to 50% of breast cancers; however, clinical research and practice underestimate this issue. Many studies have reported the loss of HER2 after neoadjuvant therapy and at metastatic relapse and identified clinicopathological variables more frequently associated with this event. Nevertheless, the biological mechanisms underlying HER2 loss are still poorly understood. HER2 downregulation, intratumoral heterogeneity, clonal selection, and true subtype switch have been suggested as potential causes of HER2 loss, but translational studies specifically investigating the biology behind HER2 loss are virtually absent. On the other side, technical pitfalls may justify HER2 loss in some of these samples. The best treatment strategy for patients with HER2 loss is currently unknown. Considering the prevalence of this phenomenon and its apparent correlation with worse outcomes, we believe that correlative studies specifically addressing HER2 loss are warranted.uk_UK
dc.language.isoenuk_UK
dc.publisherCancer Drug Resistanceuk_UK
dc.relation.ispartofseries5;P. 971-980-
dc.subjectHER2 lossuk_UK
dc.subjectbreast canceruk_UK
dc.subjectsubtype switchuk_UK
dc.subjecttumor heterogeneityuk_UK
dc.subjectclonal selectionuk_UK
dc.subjectHER2 downregulationuk_UK
dc.subjecttechnical pitfallsuk_UK
dc.titleLoss of HER2 in breast cancer: biological mechanisms and technical pitfallsuk_UK
dc.typeArticleuk_UK
Розташовується у зібраннях:Кафедра патологічної та топографічної анатомії

Файли цього матеріалу:
Файл Опис РозмірФормат 
016_cdr_ivanova_5243.png242.74 kBimage/pngПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.